The firm has three clinical trials in progress to validate the clinical utility of products it soon intends to submit for regulatory clearances to the FDA.
The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.
Luminex has since fixed the problem with a software update but a similar issue with non-specific amplification has also affected two targets on BioFire's GI panel.
Natera and Veracyte both received positive news regarding local coverage determinations from Medicare contractors, while the catalysts for Fluidigm's rise were unclear.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
The firm also posted full-year revenue growth of approximately 3 percent to $315 million, near the top end of its guidance of $310 million to $316 million and above analysts' consensus estimate.
With the acquisition, Luminex has expanded its offering of flow-based detection systems and broadened direct interactions with researchers conducting cellular analysis.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
